Profile: Jan Leschly - Cash drives the need to be number one

The SmithKline boss used to say big wasn't necessary. It is now, writes Dana Rubin

JAN LESCHLY has been a vocal proponent of the view that massive mergers and acquisitions are not a panacea for the problems of the drug industry.

So it's ironic that the 57-year-old chief executive of SmithKline Beecham should be the one to steer his drug and healthcare company towards a merger with American Home Products. Such a merger would create the world's largest drug company.

Just a few years ago, when some of the giants of the pharmaceuticals industry were combining forces, it was Leschly who cautioned against the dangers of relying on acquisitions to create growth. The surest route to prosperity, he said, was not takeovers, but new products.

"It doesn't matter how big you are," he said at the time. "I don't believe you have to have 10 per cent of the drugs market to prosper," referring to a comment by Sir Richard Sykes, then chief executive of SmithKline's rival Glaxo, which merged with Wellcome in 1995. So what has happened to change Leschly's mind?

The cost of developing new drugs, for one thing. In recent years the cost of new technologies needed to develop drugs has skyrocketed. It now takes at least $400m (pounds 240m) to $500m to bring a new drug to market.

"He's been hindered by his cash limitations," says Mark Becker, pharmaceuticals analyst at JP Morgan Securities in London. Becker said SmithKline now spends about $1bn a year on research and development, about half the spending of European rivals such as Novartis, Roche Holding and Glaxo Wellcome. "He needs to increase his R&D substantially," says Becker.

If the merger goes ahead, Leschly - a former Danish tennis champion who lives in the US - would almost certainly become chief executive of the combined companies. He could not be reached for comment.

Since becoming SmithKline chief executive in 1994, Leschly has focused on new drug development, pushing the company into the promising but so far unprofitable field of genetic research. Last May, SmithKline committed $125m to a collaboration with the biotech firm Human Genome Sciences of Rockville, Maryland.

Leschly, who played in 16 Wimbledon tennis tournaments and the Davis Cup before going into business, has won praise for his solid corporate leadership and uncompromising sense of competition.

"The best argument wins and there is no mercy," he once told an interviewer. "But some people don't understand that you play the game and afterwards you go for a beer and you're friends."

Leschly has impressed the investment community with his intense if somewhat hyperactive presentations. "He is a very inspirational person," says Jami Rubin, a pharmaceuticals analyst at Schroder & Co in New York. "You want to buy his stock. You want to work for the guy. You believe in what he's saying. He walks in a room and the place lights up."

He grew up in Odense, Denmark's second largest city, one of two sons. Older brother Peter taught him to play tennis when he was six, and within a few years he was beating his brother. He travelled the world on the tennis circuit but never got further than the quarter-finals. A family shock led him to give up the game - his brother suffered a mysterious fever and was left paralysed. Now in a wheelchair, Peter Leschly is a businessman in Denmark with a number of corporate directorships, including hi-fi firm Bang & Olufsen.

While playing tennis, Leschly had trained as a pharmacist in Copenhagen and received an MBA there. In 1972 he joined the Danish pharmaceuticals company Novo Nordisk, and in three years was president of its pharmaceuticals division.

Through a joint venture with the US company Squibb, Leschly met executives at that company and in 1979 he was asked to join them as vice-president of commercial development. His wife Lotte gave up her dental practice in Denmark, and she and their four sons moved with him to Princeton, New Jersey.

Leschly was said to be in line for the chairmanship at Squibb when the company was sold to Bristol-Myers. Instead he found himself without a job, a predicament reportedly sweetened by a payoff of several million dollars. He was 49. He once described his choices then as: "I could buy an island. Not me. I could start my own business. Or I could go back to corporate life.''

While weighing these options, he sat in on a few classes in philosophy and religion at Princeton university, where his son was studying. It turned out to be a clever public relations move, conferring on Leschly a reputation as something of a philosopher-king.

The following year he was recruited to head the pharmaceutical division of the newly-created SmithKline Beecham, the result of a merger between London-based Beecham and SmithKline Beckman of Philadelphia. It was understood that he was in line for the top job, and when Bob Bauman retired as chief executive in 1994, Leschly took over. He has been credited with making the merger work, restructuring the company, bringing in new products and moving boldly on acquisitions. Since he became chief executive, SmithKline shares have climbed from 350p to 721p, outperforming every other drug stock.

In his first five months, Leschly made two major purchases - Sterling Winthrop, maker of painkillers and other drugs, for $2.9bn, and Diversified Pharmaceutical Services, a large drug wholesaler, for $2.3bn. The first has been regarded as a far more successful buy. He also tried to buy American Cyanamid but was outbid by American Home.

In recent years SmithKline has turned to emerging technologies such as bioinformatics, combinatorial chemistry and smart screening in the search for new drugs. Leschly has said the industry can no longer wait for academia and biotech companies to develop new drugs and then buy the rights: companies must get involved at early stages of research through partnerships and alliances. He says he signs new deals just about every week although, to be fair, most of his competitors do the same.

SmithKline has done extremely well with its anti-depressant Paxil, its most successful drug in growth terms. It has also had good results with Relafen, an arthritis painkiller. Two drugs with billion-dollar potential are in the pipeline: Idoxifine, for osteoporosis and breast cancer, and Avandia, a diabetes drug.

This success, actual and potential, may lie behind his interest in merging with AHP. "Because his pipeline is so robust, he has to increase his marketing effort quite a bit," says Becker. If Jan Leschly can realise all his sales potential, invest in marketing and double R&D, he will be doing very well.

Copyright: IOS & Bloomberg

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
Arts and Entertainment
Peter Mayhew as Chewbacca alongside Harrison Ford's Han Solo in 'Star Wars'
film
News
i100
Arts and Entertainment
British actor Idris Elba is also a DJ and rapper who played Ibiza last summer
filmIdris Elba responds to James Bond rumours on Twitter
News
Hackers revealed Oscar-winning actress Lawrence was paid less than her male co-stars in American Hustle
people
Arts and Entertainment
Ellie Levenson’s The Election book demystifies politics for children
bookNew children's book primes the next generation for politics
News
Outspoken: Alexander Fury, John Rentoul, Ellen E Jones and Katy Guest
newsFrom the Scottish referendum to the Ice Bucket Challenge, our writers voice their opinions
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Sport
Adnan Januzaj and Gareth Bale
footballManchester United set to loan out Januzaj to make room for Bale - if a move for the Welshman firms up
Arts and Entertainment
Lena Headey as Cersei Lannister in Game of Thrones
film
News
i100
Sport
Yaya Sanogo, Mats Hummels, Troy Deeney and Adnan Januzaj
footballMost Premier League sides are after a striker, but here's a full run down of the ins and outs that could happen over the next month
News
Nigel Farage celebrates with a pint after early local election results in the Hoy and Helmet pub in South Benfleet in Essex
peopleHe has shaped British politics 'for good or ill'
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Selby Jennings: VP/SVP Credit Quant- NY- Investment Bank

Not specified: Selby Jennings: VP/SVP Credit Quant Top tier investment bank i...

Selby Jennings: Quantitative Research | Equity | New York

Not specified: Selby Jennings: Quantitative Research | Global Equity | New Yor...

Selby Jennings: SVP Model Validation

Not specified: Selby Jennings: SVP Model Validation This top tiered investment...

Selby Jennings: Oil Operations

Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...

Day In a Page

War with Isis: The West needs more than a White Knight

The West needs more than a White Knight

Despite billions spent on weapons, the US has not been able to counter Isis's gruesome tactics, says Patrick Cockburn
Return to Helmand: Private Davey Graham recalls the day he was shot by the Taliban

'The day I was shot by the Taliban'

Private Davey Graham was shot five times during an ambush in 2007 - it was the first, controversial photograph to show the dangers our soldiers faced in Helmand province
Revealed: the best and worst airlines for delays

Revealed: the best and worst airlines for delays

Many flyers are failing to claim compensation to which they are entitled, a new survey has found
The stories that defined 2014: From the Scottish independence referendum to the Ice Bucket Challenge, our writers voice their opinions

The stories that defined 2014

From the Scottish independence referendum to the Ice Bucket Challenge, our writers voice their opinions
Stoke-on-Trent becomes first British city to be classified as 'disaster resilient' by the United Nations

Disaster looming? Now you know where to head...

Which British city has become the first to be awarded special 'resilience' status by the UN?
Finally, a diet that works: Californian pastor's wildly popular Daniel Plan has seen his congregation greatly reduced

Finally, a diet that works

Californian pastor's wildly popular Daniel Plan has seen his congregation greatly reduced
Say it with... lyrics: The power of song was never greater, according to our internet searches

Say it with... lyrics

The power of song was never greater, according to our internet searches
Professor Danielle George: On a mission to bring back the art of 'thinkering'

The joys of 'thinkering'

Professor Danielle George on why we have to nurture tomorrow's scientists today
Monique Roffey: The author on father figures, the nation's narcissism and New Year reflections

Monique Roffey interview

The author on father figures, the nation's narcissism and New Year reflections
Introducing my anti-heroes of 2014

Introducing my anti-heroes of 2014

Their outrageousness and originality makes the world a bit more interesting, says Ellen E Jones
DJ Taylor: Good taste? It's all a matter of timing...

Good taste? It's all a matter of timing...

It has been hard to form generally accepted cultural standards since the middle of the 19th century – and the disintegration is only going to accelerate, says DJ Taylor
Olivia Jacobs & Ben Caplan: 'Ben thought the play was called 'Christian Love'. It was 'Christie in Love' - about a necrophiliac serial killer'

How we met

Olivia Jacobs and Ben Caplan
Bill Granger recipes: Our chef's breakfasts will revitalise you in time for the New Year

Bill Granger's healthy breakfasts

Our chef's healthy recipes are perfect if you've overindulged during the festive season
Transfer guide: From Arsenal to West Ham - what does your club need in the January transfer window?

Who does your club need in the transfer window?

Most Premier League sides are after a striker, but here's a full run down of the ins and outs that could happen over the next month
The Last Word: From aliens at FA to yak’s milk in the Tour, here’s to 2015

Michael Calvin's Last Word

From aliens at FA to yak’s milk in the Tour, here’s to 2015